Pharma firms ask Trump admin to safeguard China partnerships as EU pushes for quicker trials and higher spending

Pharma companies in the United States are urging the Trump administration to take steps that would protect their existing and future business arrangements with Chinese partners.

At the same time, drugmakers operating in the European Union are calling for regulatory reforms that would speed up clinical trial timelines and increase public or private investment in the sector.

Both sets of requests reflect broader concerns about how geopolitical and regulatory environments could impact drug development pipelines and market access for pharmaceutical firms worldwide.